
Thomas Cappola
Chief, Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine · University of Pennsylvania Health System
Credentials: · · · ·
History
- Present
Division of Cardiovascular Medicine · University of Pennsylvania Health System
- Present
Division of Cardiovascular Medicine · Perelman School of Medicine at the University of Pennsylvania
- Present
University of Pennsylvania Health System · Perelman School of Medicine at the University of Pennsylvania
- 2001–2002
and Blood Institute Program in Genomic Applications
- 1995–1998
- 1995–1998
Cardiovascular Disease
Chemistry) Princeton University, 1991. M.D. (Medicine) Harvard Medical School, 1995. Sc.M. (Clinical Investigation ) Johns Hopkins
- 1991–1995
Research
Systematic review or meta-analysis · Nature Communications · 2020 · 677 citations
Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms
Nature · 2002 · 635 citations
Multi-ethnic genome-wide association study for atrial fibrillation
Systematic review or meta-analysis · Nature Genetics · 2018 · 624 citations

63 papers

30 papers

22 papers · 1 as a fellow

20 papers

19 papers

18 papers

15 papers · 1 as a fellow

14 papers
Grants
- 2019–2029
National Heart, Lung, and Blood Institute · R01
Contact PI · $4.7M · University of Pennsylvania
- 1996–2027
Training Program in Cardiovascular Biology and Medicine
National Heart, Lung, and Blood Institute · T32
Contact PI · $5.7M · University of Pennsylvania
- 2019–2024
Developing Oral LT3 Therapy for Heart Failure
National Heart, Lung, and Blood Institute · R33
PI · $2.2M · University of Pennsylvania
- 2012–2020
Mid Atlantic Heart Failure Network
National Heart, Lung, and Blood Institute · U10
PI · $2.4M · University of Pennsylvania
Clinical trials
- 2011–2015
CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression
Principal investigator · Withdrawn · Phase 4
Washington University School of Medicine
- 2007–2012
Principal investigator · Completed · Phase 1, Phase 2
Celladon Corporation
- 2005–2009
Principal investigator · Completed
XDx
- 2003–2013
Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy
Study chair · Withdrawn · Phase 1, Phase 2
University of Pennsylvania


